Research

Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma

Sandra D Anderson¹ , Brett Charlton² , John M Weiler³ , Sara Nichols⁴ , Sheldon L Spector⁵ , David S Pearlman⁶ and A305 Study Group⁶

¹  Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia

²  Pharmaxis Ltd, 2/10 Rodborough Rd, Frenchs Forest, NSW 2086, Australia

³  CompleWare Corporation, PO Box 3090, Iowa City, IA 52244-3090 and University of Iowa, Iowa City, IA 52242, USA

⁴  CompleWare Corporation, PO Box 3090, Iowa City, IA 52244-3090, USA

⁵  California Allergy and Asthma Medical Group, 11645 Wilshire Blvd., Ste. 1155, Los Angeles, CA 90025, USA

⁶  Colorado Allergy & Asthma Centers, PC, 125 Rampart Way, Suite 150, Denver, CO 80230-6405, USA

author email corresponding author email

Respiratory Research 2009, 10:4doi:10.1186/1465-9921-10-4

Published:	23 January 2009

Abstract

Background

Asthma can be difficult to diagnose, but bronchial provocation with methacholine, exercise or mannitol is helpful when used to identify bronchial hyperresponsiveness (BHR), a key feature of the disease. The utility of these tests in subjects with signs and symptoms of asthma but without a clear diagnosis has not been investigated. We investigated the sensitivity and specificity of mannitol to identify exercise-induced bronchoconstriction (EIB) as a manifestation of BHR; compared this with methacholine; and compared the sensitivity and specificity of mannitol and methacholine for a clinician diagnosis of asthma.

Methods

509 people (6–50 yr) were enrolled, 78% were atopic, median FEV₁ 92.5% predicted, and a low NAEPPII asthma score of 1.2. Subjects with symptoms of seasonal allergy were excluded. BHR to exercise was defined as a ≥ 10% fall in FEV₁ on at least one of two tests, to methacholine a PC₂₀ ≤ 16 mg/ml and to mannitol a 15% fall in FEV₁ at ≤ 635 mg or a 10% fall between doses. The clinician diagnosis of asthma was made on examination, history, skin tests, questionnaire and response to exercise but they were blind to the mannitol and methacholine results.

Results

Mannitol and methacholine were therapeutically equivalent to identify EIB, a clinician diagnosis of asthma, and prevalence of BHR. The sensitivity/specificity of mannitol to identify EIB was 59%/65% and for methacholine it was 56%/69%. The BHR was mild. Mean EIB % fall in FEV₁ in subjects positive to exercise was 19%, (SD 9.2), mannitol PD₁₅ 158 (CI:129,193) mg, and methacholine PC₂₀ 2.1(CI:1.7, 2.6)mg/ml. The prevalence of BHR was the same: for exercise (43.5%), mannitol (44.8%), and methacholine (41.6%) with a test agreement between 62 & 69%. The sensitivity and specificity for a clinician diagnosis of asthma was 56%/73% for mannitol and 51%/75% for methacholine. The sensitivity increased to 73% and 72% for mannitol and methacholine when two exercise tests were positive.

Conclusion

In this group with normal FEV₁, mild symptoms, and mild BHR, the sensitivity and specificity for both mannitol and methacholine to identify EIB and a clinician diagnosis of asthma were equivalent, but lower than previously documented in well-defined populations.

Trial registration

This was a multi-center trial comprising 25 sites across the United States of America. (NCT0025229).